Zobrazeno 1 - 10
of 1 219
pro vyhledávání: '"Masahiro Endo"'
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1451-1460 (2023)
Abstract Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden
Externí odkaz:
https://doaj.org/article/6a37993073c9463ea5acbdf407d85511
Autor:
Taichi Miyawaki, Tateaki Naito, Kosei Doshita, Hiroaki Kodama, Mikiko Mori, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2064-2074 (2022)
Abstract Background Cancer cachexia and tumor burden predict efficacies of programmed cell death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors and chemotherapy or pembrolizumab in non‐small cell lung cancer (NSCLC). There are no pre
Externí odkaz:
https://doaj.org/article/055f322f354a4bb88572f00b0542def1
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (E
Externí odkaz:
https://doaj.org/article/6452d84482df43b7a070b79879e835ef
Autor:
Haruki Kobayashi, Kazushige Wakuda, Tateaki Naito, Nobuaki Mamesaya, Shota Omori, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Masahiro Endo, Hideyuki Harada, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Radiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
Abstract Background Patients with lung cancer and interstitial lung disease treated with radiotherapy are at risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILAs) and radiation pneumonitis i
Externí odkaz:
https://doaj.org/article/1bea8a610fdb4d53be92c4bcde64e9f1
Autor:
Keisuke Takiguchi, Atsushi Urikura, Tsukasa Yoshida, Yoshihiro Nakaya, Masahiro Endo, Takeshi Aramaki
Publikováno v:
Diagnostic and Interventional Radiology, Vol 26, Iss 4, Pp 333-338 (2020)
PURPOSEThe present study aimed to evaluate the scan technique of computed tomography (CT)-guided puncture procedures using partial exposure mode (PEM) on the radiation dose of the operator’s hand and image quality.METHODSRadiation dose was evaluate
Externí odkaz:
https://doaj.org/article/327f10791c984d01ac923e50e1171b9f
Autor:
Masahiro Endo
Publikováno v:
Radiological Physics and Technology. 16:137-159
Autor:
Masahiro Endo
Publikováno v:
Radiological Physics and Technology. 15:271-290
Radiation therapy for cancer using the Bragg peak of an ion beam has been making steady progress after being proposed by Robert Wilson in 1946. At the end of 2020, 12 dedicated treatment devices existed in operation worldwide, and approximately 40,00
Autor:
Taichi Miyawaki, MD, Tateaki Naito, MD, PhD, Akihro Kodama, MD, Naoya Nishioka, MD, Eriko Miyawaki, MD, Nobuaki Mamesaya, MD, Takahisa Kawamura, MD, PhD, Haruki Kobayashi, MD, Shota Omori, MD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Haruyasu Murakami, MD, PhD, Akifumi Notsu, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Masahiro Endo, MD, PhD, Kazuhisa Takahashi, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100020- (2020)
Introduction: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) i
Externí odkaz:
https://doaj.org/article/b4419d311f174e4794372d4d06ea913f
Autor:
Takahisa Kawamura, Tateaki Naito, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-3 (2019)
Abstract Background Acquired immunodeficiency associated with thymoma is a rare disorder. Here we reported a case of acquired immunodeficiency with thymoma, with an unusual pattern of low CD4+ count with normal gammaglobulin levels. Case presentation
Externí odkaz:
https://doaj.org/article/6f4aab08bafb47fe9471040f374e595c
Autor:
Tateaki Naito, Taro Okayama, Takashi Aoyama, Takuya Ohashi, Yoshiyuki Masuda, Madoka Kimura, Hitomi Shiozaki, Haruyasu Murakami, Hirotsugu Kenmotsu, Tetsuhiko Taira, Akira Ono, Kazushige Wakuda, Hisao Imai, Takuya Oyakawa, Takeshi Ishii, Shota Omori, Kazuhisa Nakashima, Masahiro Endo, Katsuhiro Omae, Keita Mori, Nobuyuki Yamamoto, Akira Tanuma, Toshiaki Takahashi
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Cancer cachexia in elderly patients may substantially impact physical function and medical dependency. The aim of this study was to estimate the impact of cachexia on activity of daily living (ADL), length of hospital stay, and in
Externí odkaz:
https://doaj.org/article/abd84b26cbf7423eaf18ccfafe7d236e